Clinical use of amrinone (a selective phosphodiesterase III inhibitor) in reconstructive surgery.
Amrinone is a selective phosphodiesterase III inhibitor that increases cyclic adenosine monophosphate by preventing its breakdown. It is effective in the treatment of congestive heart failure because of its ability to increase myocardial contractility and vascular smooth muscle relaxation. This study was designed to clarify the potential efficacy of amrinone in plastic surgery by clinically assessing its ability to enhance flap blood flow after reconstructive surgery and relieve intraoperative vasospasm. Its effects were compared with those of prostaglandin E1 and lidocaine, which are widely approved agents for improving the hemodynamics of flaps. In the first clinical study, the effects on flap blood flow after flap transfers were investigated. Twenty-six patients underwent reconstructive surgery with vascularized free or pedicled flaps. Blood flow was measured before and 60 minutes after intravenous infusion of lactated Ringer solution (control), amrinone (10 microg/kg/min), or prostaglandin E1 (10 ng/kg/min) using a laser Doppler flowmeter. In the second study, the effects on relief of vasospasm during operation were evaluated. The blood flow of 28 island flaps was measured by laser Doppler flowmetry immediately after flap elevation and 10 minutes after topical application of saline (control), amrinone (5 mg/ml), or lidocaine (10%) to the pedicle in an attempt to resolve the vasospasm. In both clinical studies, the effects of amrinone were statistically no less than those of prostaglandin E1 and lidocaine. The results show that amrinone positively influences the microcirculatory blood flow of transferred flaps and relieves intraoperative vasospasm in clinical cases. The present study suggests that amrinone could be useful for postoperative and intraoperative care in reconstructive surgery.
Ichioka
S
S
Department of Plastic and Reconstructive Surgery, Saitama Medical School, Iruma-gun, Japan. ichioka-stm@umin.ac.jp
Nakatsuka
T
T
Ohura
N
N
Sato
Y
Y
Harii
K
K
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D000328:Adult; D000368:Aged; D000527:Alprostadil / Q000627:therapeutic use; D000676:Amrinone / Q000627:therapeutic use*; D001783:Blood Flow Velocity; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3; D005260:Female; D006801:Humans; D007431:Intraoperative Complications / Q000188:drug therapy; D017078:Laser-Doppler Flowmetry; D008012:Lidocaine / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D019651:Plastic Surgery Procedures; D013524:Surgical Flaps / Q000098:blood supply*; D014661:Vasoconstriction / Q000187:drug effects; D014665:Vasodilator Agents / Q000627:therapeutic use*
D010726:Phosphodiesterase Inhibitors; D014665:Vasodilator Agents; D008012:Lidocaine; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3; D000527:Alprostadil; D000676:Amrinone